Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

316 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A single course of remission reinduction chemotherapy for acute myelogenous leukemia relapsing after allogeneic bone marrow transplantation is complicated by graft-versus-host disease and followed by sustained complete remission.
Vandenberghe P, Verhoef GE, Emonds MP, Demuynck H, Zachée P, De Wolf-Peeters C, Decorte R, Cassiman JJ, Boogaerts MA. Vandenberghe P, et al. Leukemia. 1997 Oct;11(10):1775-8. doi: 10.1038/sj.leu.2400810. Leukemia. 1997. PMID: 9324300
Prognostic value of positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose ([18F]FDG) after first-line chemotherapy in non-Hodgkin's lymphoma: is [18F]FDG-PET a valid alternative to conventional diagnostic methods?
Spaepen K, Stroobants S, Dupont P, Van Steenweghen S, Thomas J, Vandenberghe P, Vanuytsel L, Bormans G, Balzarini J, De Wolf-Peeters C, Mortelmans L, Verhoef G. Spaepen K, et al. Among authors: vandenberghe p. J Clin Oncol. 2001 Jan 15;19(2):414-9. doi: 10.1200/JCO.2001.19.2.414. J Clin Oncol. 2001. PMID: 11208833
Can positron emission tomography with [(18)F]-fluorodeoxyglucose after first-line treatment distinguish Hodgkin's disease patients who need additional therapy from others in whom additional therapy would mean avoidable toxicity?
Spaepen K, Stroobants S, Dupont P, Thomas J, Vandenberghe P, Balzarini J, De Wolf-Peeters C, Mortelmans L, Verhoef G. Spaepen K, et al. Among authors: vandenberghe p. Br J Haematol. 2001 Nov;115(2):272-8. doi: 10.1046/j.1365-2141.2001.03169.x. Br J Haematol. 2001. PMID: 11703321 Free article.
316 results